Ukraine Regional Chapter of ISPOR: presenting activities during ISPOR 22nd Annual International meeting in Boston

_Oresta Piniazhko, PhD, President of Ukraine Regional Chapter of ISPOR, Assistant Professor, Danylo Halytsky Lviv National Medical University, Expert Committee of Ministry of Health of Ukraine; Olha Zalis’ka, PhD, DSci, Past-President and Founder of Ukraine Regional Chapter of ISPOR, Professor, Danylo Halytsky Lviv National Medical University_

ISPOR 22nd Annual International meeting in Boston was a great opportunity for members of Ukraine Regional Chapter of ISPOR, most of its members representing the Department of Management and Economy of Pharmacy, Drug Technology and Pharmacoeconomics at Danylo Halytsky Lviv National Medical University.

Members of the delegation from Ukraine included: Past-President and Founder of Ukraine Regional Chapter of ISPOR, Professor Olha Zalis’ka, PhD, DSci, President of Ukraine Regional Chapter, Assistant Professor Oresta Piniazhko, PhD, President of ISPOR Ukraine Student Chapter Olha Brezden, chapter members – Andrew Solovej (Lviv Polytechnic National University), Associate Professor Inna Irynchyna, PhD (Kyiv National Economic University named after Vadym Hetman), Hryhoriy Irynchyn (PhD, UkrMedinform, Kyiv).

It should be noted that the official agenda included the joint presentations delivered by ISPOR Chapters from CEE Network: Ukraine, Hungary and Serbia. The meeting was attended by special guests: Julia Chamova, Director of EMEA Global Networks, ISPOR; Vlad Zah, Chair of ISPOR CEE Network; Nadia Maldonado, Assistant Manager of Global Networks, ISPOR; Professor Guenka Petrova, President of Bulgaria Chapter; Bertalan Nemeth, President-Elect, ISPOR Hungary Chapter (Syreon Research Institute), Professor Imre Boncz (University Pécs, Hungary), Oleksandr Topachevskyi (Digital Health Outcomes®, Kyiv).

Julia Chamova warmly welcomed the meeting participants and wished them all to get engaged in many interesting discussions. The meeting and the presentations gave participants the opportunity to share the experience of recent achievements in HTA in the region, and discuss the introduction of MCDA in decision-making and its role in the reimbursement of new medicines in CEE countries.